Meaghan Hancock
Assistant Professor
Vaccine and Gene Therapy Institute, Oregon Health & Science University, United States
Wednesday, August 4
8:05-8:30
Meaghan Hancock
Meaghan Hancock is an Assistant Professor at the Vaccine and Gene Therapy Institute (VGTI) at Oregon Health and Science University in Beaverton, Oregon. She received her B. Sc. in Molecular Biology and Biotechnology from McMaster University, Hamilton, Ontario, Canada in 2004. During her undergraduate studies she worked in the laboratory of Dr. Karen Mossman studying viral mediated activation of IRF3. Her Ph.D. research was conducted in the laboratory of Dr. Jim Smiley at the University of Alberta, Edmonton, Alberta, Canada where she studied the roles of herpes simplex virus proteins VP16 and ICP0 in overcoming innate barriers to viral gene expression. She began her post-doctoral training at the VGTI in 2010 in the laboratory of Dr. Jay Nelson, studying human cytomegalovirus (CMV) miRNAs. She is currently investigating the role of HCMV miRNAs in modulating cellular signaling pathways during latency and reactivation in CD34+ hematopoietic progenitor cells. Additionally, she is also involved in developing CMV-based vaccines for HIV, SARS-CoV2 and other pathogens and uses miRNA targeting to alter CMV tropism in order to better understand the unique immune responses elicited by CMV-based vaccine vectors.